万基遗传股票讨论区

The acquisition is expected to enable Myriad to more effectively scale and grow its tumor profiling offerings to complement its oncology portfolio of hereditary cancer and companion diagnostic testing options.

Dr. Daneker's leadership is expected to drive innovation, growth, and development of the company's oncology portfolio, including expansions into liquid biopsy and minimal residual disease testing. His experience and track record are anticipated to boost the company's strategy with health systems and large oncology practices.

The acquisition is set to spur innovation, growth, and further development of Myriad's oncology portfolio. It will also enhance the scaling and growth of their tumor profiling and liquid biopsy tests, including operational efficiencies, reimbursement benefits and new clinical development opportunities.

The low P/S ratio for Myriad Genetics is likely due to its subpar revenue performance and limited future growth expectations, which have suppressed its share price. These conditions could hinder a significant rise in the share price in the near future.

Though Myriad Genetics maintains a cash surplus, doubt arises from its lack of free cash flow, negative EBIT, and significant liabilities.

CEO Paul Diaz is confident in Raha's capability to enhance profitability and expand the company, leveraging his substantial experience in diagnostics. Diaz considers Raha will introduce new ideas and expertise to progress current business missions and operational excellence.

Goldman Sachs were very encouraged by the presentation and lab tour at the Investor Day. While the stock could benefit from a clean quarter where the improved organic growth profile is highlighted,  the market should be ascribing more credit to the transformation in the business over the past few years. Goldman see an improving financial profile as previous investments in commercial, revenue cycle management, lab automation and R&D contribute to growth...